REGENXBIO to Participate in Upcoming Investor Conferences
Fireside chat: Wednesday, March 3, 2021 at
Fireside chat: Tuesday, March 9, 2021 at
Morgan Stanley Virtual Healthcare Corporate Access Day
Live webcasts of the Raymond James and Barclays fireside chats can be accessed in the Investors section of
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV® Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Investor Relations and Corporate Communications
View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301234852.html